A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301]
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Voretigene neparvovec (Primary)
- Indications Leber congenital amaurosis
- Focus Registrational; Therapeutic Use
- Sponsors Spark Therapeutics
- 31 Jul 2017 According to a Spark Therapeutics media release, the company has submitted a Marketing Authorization Application (MAA) to the EMA for LUXTURNA for the treatment of patients with vision loss due to Leber congenital amaurosis or retinitis pigmentosa caused by confirmed biallelic RPE65 mutations.
- 20 Jul 2017 According to a Spark Therapeutics media release, FDA's Office of Tissues and Advanced Therapies currently is reviewing the BLA for LUXTURNA under a Priority Review designation with a Prescription Drug User Fee Act (PDUFA) action date of Jan. 12, 2018.
- 17 Jul 2017 According to a Spark Therapeutics media release, the U.S. FDA has accepted for filing the Biologics License Application (BLA) and granted Priority Review for voretigene neparvovec for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease (IRD). This submission based on the data from three clinical trials including this study.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History